Research
An Inhaled RNA Drug Aims to Fix Cystic Fibrosis a Step Earlier
Aptar Pharma is joining Aceso Therapeutics to develop ACT-101 — an inhalable oligonucleotide that works at the RNA level, before the faulty CF protein is even built.